Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Nervous system drugs >  Other nervous system drugs >  Nusinersen

Nusinersen

Basic information Safety Supplier Related

Nusinersen Basic information

Product Name:
Nusinersen
Synonyms:
  • NU
  • Nusinersen
  • Nusinersen USP/EP/BP
  • Nociceptive sodium( Nociceptive sodium)
  • Nusinersen Impurity
CAS:
1258984-36-9
MF:
C234H340N61O128P17S17
MW:
7127.194237
Mol File:
1258984-36-9.mol
More
Less

Nusinersen Chemical Properties

storage temp. 
Store at -20°C
InChI
InChI=1S/C234H340N61O128P17S17/c1-106-66-278(224(308)261-178(106)235)205-162(356-50-32-338-14)144(119(391-205)79-373-425(320,442)407-143-117(77-296)389-204(161(143)355-49-31-337-13)282-70-110(5)193(298)271-228(282)312)410-431(326,448)383-89-129-154(172(366-60-42-348-24)215(401-129)289-99-254-135-182(239)246-95-250-186(135)289)419-436(331,453)379-81-121-145(163(357-51-33-339-15)206(393-121)279-67-107(2)179(236)262-225(279)309)408-426(321,443)375-83-123-149(167(361-55-37-343-19)210(395-123)284-72-112(7)195(300)273-230(284)314)413-429(324,446)378-86-125-150(168(362-56-38-344-20)211(397-125)285-73-113(8)196(301)274-231(285)315)414-430(325,447)377-85-124-148(166(360-54-36-342-18)209(396-124)283-71-111(6)194(299)272-229(283)313)412-428(323,445)374-80-120-147(165(359-53-35-341-17)208(392-120)281-69-109(4)181(238)264-227(281)311)411-432(327,449)384-90-130-155(173(367-61-43-349-25)216(402-130)290-100-255-136-183(240)247-96-251-187(136)290)420-437(332,454)381-87-127-152(170(364-58-40-346-22)213(399-127)287-75-115(10)198(303)276-233(287)317)415-433(328,450)385-91-131-157(175(369-63-45-351-27)218(403-131)292-102-257-138-185(242)249-98-253-189(138)292)422-440(335,457)386-92-132-156(174(368-62-44-350-26)217(404-132)291-101-256-137-184(241)248-97-252-188(137)291)421-438(333,455)382-88-128-153(171(365-59-41-347-23)214(400-128)288-76-116(11)199(304)277-234(288)318)417-435(330,452)388-94-134-159(177(371-65-47-353-29)220(406-134)295-105-260-141-192(295)267-223(245)270-202(141)307)423-439(334,456)380-82-122-146(164(358-52-34-340-16)207(394-122)280-68-108(3)180(237)263-226(280)310)409-427(322,444)376-84-126-151(169(363-57-39-345-21)212(398-126)286-74-114(9)197(302)275-232(286)316)416-434(329,451)387-93-133-158(176(370-64-46-352-28)219(405-133)294-104-259-140-191(294)266-222(244)269-201(140)306)418-424(319,441)372-78-118-142(297)160(354-48-30-336-12)203(390-118)293-103-258-139-190(293)265-221(243)268-200(139)305/h66-76,95-105,117-134,142-177,203-220,296-297H,30-65,77-94H2,1-29H3,(H,319,441)(H,320,442)(H,321,443)(H,322,444)(H,323,445)(H,324,446)(H,325,447)(H,326,448)(H,327,449)(H,328,450)(H,329,451)(H,330,452)(H,331,453)(H,332,454)(H,333,455)(H,334,456)(H,335,457)(H2,235,261,308)(H2,236,262,309)(H2,237,263,310)(H2,238,264,311)(H2,239,246,250)(H2,240,247,251)(H2,241,248,252)(H2,242,249,253)(H,271,298,312)(H,272,299,313)(H,273,300,314)(H,274,301,315)(H,275,302,316)(H,276,303,317)(H,277,304,318)(H3,243,265,268,305)(H3,244,266,269,306)(H3,245,267,270,307)/t117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?,440?/m1/s1
InChIKey
WWFDJIVIDXJAQR-FFWSQMGZSA-N
SMILES
S=P(O[H])(OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3=C(N([H])[H])N=C([H])N=C23)O1)OC([H])([H])C([H])([H])OC([H])([H])[H])OP(O[H])(OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C(N([H])C(C(C([H])([H])[H])=C2[H])=O)=O)O1)OC([H])([H])C([H])([H])OC([H])([H])[H])OP(O[H])(OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3C(N([H])C(N([H])[H])=NC2=3)=O)O1)OC([H])([H])C([H])([H])OC([H])([H])[H])OP(O[H])(OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C(N=C(C(C([H])([H])[H])=C2[H])N([H])[H])=O)O1)OC([H])([H])C([H])([H])OC([H])([H])[H])OP(O[H])(OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C(N([H])C(C(C([H])([H])[H])=C2[H])=O)=O)O1)OC([H])([H])C([H])([H])OC([H])([H])[H])OP(O[H])(OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3C(N([H])C(N([H])[H])=NC2=3)=O)O1)OC([H])([H])C([H])([H])OC([H])([H])[H])OP(O[H])(OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3C(N([H])C(N([H])[H])=NC2=3)=O)O1)OC([H])([H])C([H])([H])OC([H])([H])[H])O[H])=S)=S)=S)=S)=S)=S)O[C@]1([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]2([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]3([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]4([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]5([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]6([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]7([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]8([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]9([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]%10([H])[C@@]([H])(C([H])([H])OP(O[H])(O[C@]%11([H])[C@@]([H])(C([H])([H])O[H])O[C@]([H])([C@]%11([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N%11C(N([H])C(C(C([H])([H])[H])=C%11[H])=O)=O)=S)O[C@]([H])([C@]%10([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N%10C(N=C(C(C([H])([H])[H])=C%10[H])N([H])[H])=O)=S)O[C@]([H])([C@]9([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N9C([H])=NC%10=C(N([H])[H])N=C([H])N=C9%10)=S)O[C@]([H])([C@]8([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N8C(N=C(C(C([H])([H])[H])=C8[H])N([H])[H])=O)=S)O[C@]([H])([C@]7([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N7C(N([H])C(C(C([H])([H])[H])=C7[H])=O)=O)=S)O[C@]([H])([C@]6([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N6C(N([H])C(C(C([H])([H])[H])=C6[H])=O)=O)=S)O[C@]([H])([C@]5([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N5C(N([H])C(C(C([H])([H])[H])=C5[H])=O)=O)=S)O[C@]([H])([C@]4([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N4C(N=C(C(C([H])([H])[H])=C4[H])N([H])[H])=O)=S)O[C@]([H])([C@]3([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N3C([H])=NC4=C(N([H])[H])N=C([H])N=C34)=S)O[C@]([H])([C@]2([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N2C(N([H])C(C(C([H])([H])[H])=C2[H])=O)=O)=S)O[C@]([H])([C@]1([H])OC([H])([H])C([H])([H])OC([H])([H])[H])N1C([H])=NC2=C(N([H])[H])N=C([H])N=C12
More
Less

Nusinersen Usage And Synthesis

Description

Nusinersen is a prescription medication used to treat adult and paediatric spinal muscular atrophy (SMA) by improving peripheral muscle function.SMA is caused by a mutation in a gene called SMN1, which encodes for a protein important for motor neuron survival (survival motor neuron or SMN). Although a nearly identical gene (SMN2) serves as a backup to SMN1, it produces a shorter, less stable protein that does not fully compensate for the loss of the full-length protein normally produced by the SMN1 gene. In contrast, Nusinersen is an antisense oligonucleotide agent that modifies the pre-messenger RNA splicing of the SMN2 gene, thereby facilitating increased production of full-length SMN proteins[1-2].

Uses

Nusinersen can be used to treat adult and paediatric spinal muscular atrophy (SMA) and is also able to improve respiratory function and slow the decline in lung function in paediatric SMA[1].

References

[1] MICHELLE A FARRAR; Matthew C K. Treating adults with spinal muscular atrophy with nusinersen.[J]. Journal of Neurology, Neurosurgery, and Psychiatry, 2020. DOI:10.1136/jnnp-2020-324036.
[2] ARCHANA CHACKO. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.[J]. Thorax, 2022. DOI:10.1136/thoraxjnl-2020-216564.

NusinersenSupplier

Apextide Co Ltd Gold
Tel
15700198315
Email
shubin.zhao@apextide.com
Biopole Pharmatech Co., Ltd. Gold
Tel
0512-65974739-0 15151475053
Email
mengqi_biopole@163.com
Shanghai Zhibang Biological Medicine Co., LTD
Tel
021-54285032 18116461626
Email
25493162@qq.com
Nanjing Meihao Pharmaceutical Technology Co., Ltd.
Tel
meitaochem@126.com
Email
meitaochem@126.com
Dideu Industries Group Limited
Tel
+86-29-89586680 +86-15129568250
Email
1026@dideu.com